Abstract:Prostaglandin E2 (PGE2) is involved in numerous physiological and pathological processes of the kidney via its four receptors. A previous study has suggested that a defect in the PGE2 receptor 1 (EP1) gene markedly suppressed the transforming growth factor‑β1 (TGF‑β1)‑induced mesangial cell (MC) proliferation and extracellular matrix aggregation. Therefore, the present study aimed to adopt a pharmacological method of specifically suppressing or activating the EP1 receptor to further verify and demonstrate these results. The EP1 receptor antagonist SC‑19220 and EP1 receptor agonist 17‑phenyl‑trinor‑PGE2 ethyl amide (17‑pt‑PGE2) were selectively used to treat five‑sixths nephrectomy renal fibrosis model mice and TGF‑β1‑stimulated MCs. An Alpha screen PGE2 assay kit, flow cytometry, western blotting and immunohistochemical techniques were adopted to perform in vivo and in vitro experiments. The present results suggested that compared with the control group, the selective EP1 receptor antagonist SC‑19220 improved renal function, markedly reduced the plasma blood urea nitrogen and creatinine levels (P<0.05) and alleviated glomerulosclerosis (P<0.05). By contrast, the EP1 receptor agonist 17‑pt‑PGE2 aggravated renal dysfunction and glomerulosclerosis (P<0.05). To verify the renal protection mechanisms mediated by suppression of the EP1 receptor, the expression levels of endoplasmic reticulum stress (ERS)‑related proteins, including chaperone glucose‑regulated protein 78 (GRP78), transient receptor potential channel 1 (TRPC1) and protein kinase R‑like endoplasmic reticulum kinase (PERK), were further evaluated histologically. The expression of GRP78, TRPC1 and PERK in the antagonist treatment group were markedly downregulated (P<0.05), whereas those in the agonist treatment group were upregulated (P<0.05). The present in vitro experiments demonstrated that, compared with the control group, the EP1 receptor antagonist suppressed the expression of GRP78, TRPC1 and PERK (P<0.05), reduced the production of PGE2 (P<0.05) and decreased the MC apoptosis rate (P<0.05), thus alleviating TGF‑β1‑stimulated MC injury. Consequently, consistent with previous results, selectively antagonizing the EP1 receptor improved renal function and mitigated glomerulosclerosis, and its potential mechanism might be associated with the suppression of ERS.

Microsomal Prostaglandin E Synthase-1–Derived PGE 2 Inhibits Vascular Smooth Muscle Cell Calcification

Cyclooxygenase-2 Induces Angiogenesis in Pancreatic Cancer Mediated by Prostaglandin E-2

Peroxisome Proliferator-Activated Receptor-γ Coactivator-1α Inhibits Vascular Calcification Through Sirtuin 3-Mediated Reduction of Mitochondrial Oxidative Stress.

Prostaglandin E2 Receptor EP2 Mediates the Effect of Cyclooxygenase 2 on Secondary Parathyroid Hyperplasia in End-Stage Renal Disease.

Increased β-adrenergic stimulation augments vascular smooth muscle cell calcification via PKA/CREB signalling

High Phosphate-Induced Downregulation of PPARγ Contributes to CKD-associated Vascular Calcification

Cyclooxygenase-2 in endothelial and vascular smooth muscle cells restrains atherogenesis in hyperlipidemic mice

Effect of selective inhibition or activation of PGE2 EP1 receptor on glomerulosclerosis

Microsomal prostaglandin E2 synthase-1 and its inhibitors: Molecular mechanisms and therapeutic significance

Inhibition of Cyclooxygenase-2 in Hematopoietic Cells Results in Salt-Sensitive Hypertension.

Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis

Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells.

Targeted Disruption of the Prostaglandin E2 E-prostanoid 2 Receptor Exacerbates Vascular Neointimal Formation in Mice.

PGE2 activates EP4 in subchondral bone osteoclasts to regulate osteoarthritis

Mechanisms of miR-29a-5p involvement in osteogenic phenotype transformation and cellular regulation of vascular smooth muscle and thus influencing calcification in VSMCs in chronic kidney disease

Modulation of Enzyme-Catalyzed Synthesis of Prostaglandins by Components Contained in Kidney Microsomal Preparations

Peroxisome Proliferator-Activated Receptor Γ Ligands Retard Cultured Vascular Smooth Muscle Cells Calcification Induced by High Glucose

MicroRNA-214 targets COX-2 to antagonize indoxyl sulfate (IS)-induced endothelial cell apoptosis

Selective cyclooxygenase-2 inhibitor use and progression of renal function in patients with chronic kidney disease: a single-center retrospective cohort study

CCAAT/Enhancer-Binding Protein Alpha Is a Novel Regulator of Vascular Smooth Muscle Cell Osteochondrogenic Transition and Vascular Calcification

Mitochondrial Reactive Oxygen Species Promote P65 Nuclear Translocation Mediating High-Phosphate-induced Vascular Calcification in Vitro and in Vivo.